Bronchial thermoplasty in severe asthma: a real-world study on efficacy and gene profiling

Table 2 Clinical criteria for definition of patients with a better response to BT

T2-high endotype				T2-low endotype
Patient ID	OCS reduction at T12 versus baseline (%)	Number of exacerbations at T12 versus T2	ACQ score at T12	Patient ID	OCS reduction at T12 versus baseline (%)	Number of exacerbations at T12 versus T2	ACQ score at T12
1	100	1	2.0	2	50	1	2.5
3	100	0	1.5	5	80	2	2.0
4	0	2	2.4	9	100	1	1.0
6	50	1	2.6	11	100	0	2.6
7	100	0	0	13	100	1	1.6
8	100	1	0.6	14	50	0	1.4
10	50	2	1.2	15	0	2	1.0
12	100	0	1.6	18	100	1	2.0
16	75	1	1.2	19	NA	0	1.2
17	75	2	1.4	20	100	1	1.8
25	50	2	1.4	21	75	1	1.2
26	100	2	2.1	22	NA	1	1.6
27	50	3	2.5	23	50	1	1.6
				24	100	2	1.2
Total responder: 22 (81%)

Patients were classified as responders when they had at least 2 of the 3 outcome measures: (1) ACQ score < 1.5 at T12; (2) < 2 asthma exacerbations at T12 versus T2; (3) OCSs reduction of at least 50% at T12 versus baseline. Patients who did not receive OCSs at baseline (NA) were classified as responders when they had one of the other outcome measures
OCS oral corticosteroids, NA (not applicable) patients who did not take OCS at baseline, Colored patient boxes = responders

ISSN: 1710-1492